Additionally, in rhabdomyosarcoma, CXCR2 inhibitor can inhibit CD11b+Ly6G+CXCR2+ MDSCs recruiting to tumor tissues and significantly enforce the anti-programmed cell death protein 1 (anti-PD1) immunotherapy efficacy in vivo [19]. Here, CXCR2 is linked to rhabdomyosarcoma.